Developer docs
API playgroundTry for free, no card

Search company profiles

HotHouse Therapeutics

Full company profile

uuid00uo6wi

Namestring
HotHouse Therapeutics
Legal namestring
Hot House Therapeutics
Websiteurl
hothousetx.com
Company typeenum
Private
Founded yearint
2025
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNorwich, United Kingdom
HQ citystring
Norwich
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, plant bioengineering, synthetic biology, therapeutic compounds, vaccine adjuvants
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
AI-Driven Drug Discovery Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Discovery Partnerships and Licensing
TypeLicensing Royalties
Description

HotHouse Therapeutics generates revenue through partnerships with pharmaceutical and biotech companies, offering access to their AI-driven plant-based drug discovery platform for novel therapeutic development. Revenue derived from collaborative research agreements, milestone payments, and potential licensing of discovered compounds.

hothousetx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

HotHouse Therapeutics operates a dual-platform drug discovery architecture combining AI with plant-based bioengineering. The BotanAI platform initiates and optimizes compound design, while BotanBio delivers scalable chemistry through novel transient and stable plant expression systems. The company reprograms plant biosynthetic pathways to produce therapeutic compounds—including vaccine adjuvants and new-to-nature molecules—that are inaccessible through traditional chemical synthesis, moving from digital concept to high-purity compounds in days rather than years.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Days vs years to move from digital concept to high-purity compound
+1 more record
Product overview1 text field

HotHouse Therapeutics operates a dual-platform architecture consisting of BotanAI and BotanBio. BotanAI serves as the AI-driven design and optimisation engine that transforms plants into sustainable biofactories for identifying next-generation therapeutics. BotanBio delivers the scalable chemistry production, combining AI-generated designs with two novel plant expression systems (transient for development and stable for production) to translate complex chemistry through to GMP. Together, these platforms enable the company to move from digital concept to high-purity compounds in days rather than years.

Product and service2 records
1BotanAI
CategoryAI drug discovery platform
Description

AI-driven platform that transforms plants into sustainable biofactories, unlocking vaccine adjuvants and new-to-nature therapeutics by initiating and optimising compound design and delivery. Identifies the next generation of therapeutics through AI-guided plant biosynthesis for pharmaceutical, biotech, and global health partners.

2BotanBio
CategoryBiomanufacturing and chemistry delivery platform
Description

Chemistry delivery platform providing scalable, sustainable solutions from vaccine adjuvants to small molecule therapeutics. Combines AI-generated designs with two novel plant expression systems—transient for development and stable for production—to translate complex chemistry through to GMP for pharmaceutical, biotech, and global health customers.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-28
Description

HotHouse Therapeutics implemented CDD Vault, a cloud-based informatics platform, to enhance R&D operations. The platform centralizes experimental and computational data, accelerates lead design decisions, improves collaboration with partners, and maintains full control of intellectual property. CDD Vault supports HotHouse's AI-driven plant biosynthesis work by managing complex datasets.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

HotHouse Therapeutics is a UK biotech spin-out from the John Innes Centre, a world-leading research institute in plant science and microbiology. The company leverages research and expertise originating from this academic institution, with Chief Science Officer Professor Anne Osbourn OBE FRS FLS having established the foundational science.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs is an Alphabet-backed AI drug discovery company with deep computational chemistry capability and large-pharma partnerships. It competes for the same enterprise partnership mindshare that HotHouse is targeting with its plant-based angle.

TypeDirect peer
Description

Antheia engineers yeast-based synthetic biology platforms to produce active pharmaceutical ingredients currently sourced from plants. Its end-to-end synbio-to-pharma pipeline and focus on plant-derived APIs overlap with HotHouse's plant expression to GMP ambition.

TypeBroad incumbent
Description

Recursion combines high-throughput biology with AI for drug discovery at scale across multiple therapeutic areas. Its AI-native discovery model and partnership-based commercialisation mirror HotHouse's go-to-market, though its scale and capital base dwarf HotHouse.

TypeBroad incumbent
Description

Schrödinger provides computational chemistry and physics-based simulation software used by pharma for drug discovery. While its software-and-services model differs, its pursuit of new-to-nature molecules through computation parallels HotHouse's AI design layer.

TypeEmerging player
Description

Atomwise uses AI for small-molecule drug discovery and partners with pharma on novel compound identification. Its partnership-led GTM and AI-native discovery approach is comparable to HotHouse's platform model, with overlap in pharma buyer relationships.

TypeBroad incumbent
Description

Ginkgo Bioworks operates a broad synthetic biology platform for programming cells across pharma, agriculture and industrial markets. Its end-to-end synbio infrastructure and codebase ambition mirror HotHouse's pathway-engineering architecture at much larger scale.

TypeDirect peer
Description

Ayana Bio applies synthetic biology to plant-derived bioactive ingredients for health and wellness applications, directly comparable to HotHouse's plant biosynthetic pathway engineering approach. Both companies target complex, plant-made molecules inaccessible to traditional chemistry.

TypeBroad incumbent
Description

Insilico Medicine is a leading AI-driven drug discovery company with its own generative chemistry platform and pipeline. Its broader small-molecule focus contrasts with HotHouse's plant-biosynthesis angle, but the AI-for-molecules overlap makes it a key adjacent peer.

TypeDirect peer
Description

Brightseed uses AI to discover bioactive compounds in plants and has built a profile of plant-derived small molecules for health applications. The combination of AI + plant bioactives for therapeutic discovery mirrors HotHouse's platform thesis.

TypeEmerging player
Description

Cradle applies generative AI to protein and biologics design, combining ML with wet-lab iteration. Its AI + biology productisation ethos is comparable, though its modality focus is proteins rather than plant small molecules.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HotHouse Therapeutics

AI-Driven Drug Discovery Platformhothousetx.com

HotHouse Therapeutics firmographics

Firmographics
Name
HotHouse Therapeutics
Legal name
Hot House Therapeutics
Website
https://hothousetx.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

HotHouse Therapeutics industry classification

Industry
Product category
AI-Driven Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Plant bioengineering
  • Synthetic biology
  • Therapeutic compounds
  • Vaccine adjuvants

Where HotHouse Therapeutics is headquartered

Location

Headquarters

HQ city
Norwich
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

HotHouse Therapeutics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Discovery Partnerships and Licensing: HotHouse Therapeutics generates revenue through partnerships with pharmaceutical and biotech companies, offering access to their AI-driven plant-based drug discovery platform for novel therapeutic development. Revenue derived from collaborative research agreements, milestone payments, and potential licensing of discovered compounds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

HotHouse Therapeutics product offering

Product offering

Core offering

HotHouse Therapeutics operates a dual-platform drug discovery architecture combining AI with plant-based bioengineering. The BotanAI platform initiates and optimizes compound design, while BotanBio delivers scalable chemistry through novel transient and stable plant expression systems. The company reprograms plant biosynthetic pathways to produce therapeutic compounds—including vaccine adjuvants and new-to-nature molecules—that are inaccessible through traditional chemical synthesis, moving from digital concept to high-purity compounds in days rather than years.

Product overview

HotHouse Therapeutics operates a dual-platform architecture consisting of BotanAI and BotanBio. BotanAI serves as the AI-driven design and optimisation engine that transforms plants into sustainable biofactories for identifying next-generation therapeutics. BotanBio delivers the scalable chemistry production, combining AI-generated designs with two novel plant expression systems (transient for development and stable for production) to translate complex chemistry through to GMP. Together, these platforms enable the company to move from digital concept to high-purity compounds in days rather than years.

Differentiator

Problem solved

Functional benefit

Products and services

  • BotanAI AI-driven platform that transforms plants into sustainable biofactories, unlocking vaccine adjuvants and new-to-nature therapeutics by initiating and optimising compound design and delivery. Identifies the next generation of therapeutics through AI-guided plant biosynthesis for pharmaceutical, biotech, and global health partners.
  • BotanBio Chemistry delivery platform providing scalable, sustainable solutions from vaccine adjuvants to small molecule therapeutics. Combines AI-generated designs with two novel plant expression systems—transient for development and stable for production—to translate complex chemistry through to GMP for pharmaceutical, biotech, and global health customers.

Quantifiable outcome

  • Days vs years to move from digital concept to high-purity compound
  • +1 more outcomes

Companies that use HotHouse Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

HotHouse Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

HotHouse Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Collaborative Drug Discovery (CDD)coreTechnology or Integration · 28 October 2025HotHouse Therapeutics implemented CDD Vault, a cloud-based informatics platform, to enhance R&D operations. The platform centralizes experimental and computational data, accelerates lead design decisions, improves collaboration with partners, and maintains full control of intellectual property. CDD Vault supports HotHouse's AI-driven plant biosynthesis work by managing complex datasets.
  • John Innes CentrecoreStrategic or Co-development PartnerHotHouse Therapeutics is a UK biotech spin-out from the John Innes Centre, a world-leading research institute in plant science and microbiology. The company leverages research and expertise originating from this academic institution, with Chief Science Officer Professor Anne Osbourn OBE FRS FLS having established the foundational science.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

HotHouse Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Isomorphic Labs: Isomorphic Labs is an Alphabet-backed AI drug discovery company with deep computational chemistry capability and large-pharma partnerships. It competes for the same enterprise partnership mindshare that HotHouse is targeting with its plant-based angle.
  • Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI for drug discovery at scale across multiple therapeutic areas. Its AI-native discovery model and partnership-based commercialisation mirror HotHouse's go-to-market, though its scale and capital base dwarf HotHouse.
  • Schrödinger: Schrödinger provides computational chemistry and physics-based simulation software used by pharma for drug discovery. While its software-and-services model differs, its pursuit of new-to-nature molecules through computation parallels HotHouse's AI design layer.
  • Ginkgo Bioworks: Ginkgo Bioworks operates a broad synthetic biology platform for programming cells across pharma, agriculture and industrial markets. Its end-to-end synbio infrastructure and codebase ambition mirror HotHouse's pathway-engineering architecture at much larger scale.
  • Insilico Medicine: Insilico Medicine is a leading AI-driven drug discovery company with its own generative chemistry platform and pipeline. Its broader small-molecule focus contrasts with HotHouse's plant-biosynthesis angle, but the AI-for-molecules overlap makes it a key adjacent peer.

Direct peers

  • Antheia: Antheia engineers yeast-based synthetic biology platforms to produce active pharmaceutical ingredients currently sourced from plants. Its end-to-end synbio-to-pharma pipeline and focus on plant-derived APIs overlap with HotHouse's plant expression to GMP ambition.
  • Ayana Bio: Ayana Bio applies synthetic biology to plant-derived bioactive ingredients for health and wellness applications, directly comparable to HotHouse's plant biosynthetic pathway engineering approach. Both companies target complex, plant-made molecules inaccessible to traditional chemistry.
  • Brightseed: Brightseed uses AI to discover bioactive compounds in plants and has built a profile of plant-derived small molecules for health applications. The combination of AI + plant bioactives for therapeutic discovery mirrors HotHouse's platform thesis.

Emerging players

  • Atomwise: Atomwise uses AI for small-molecule drug discovery and partners with pharma on novel compound identification. Its partnership-led GTM and AI-native discovery approach is comparable to HotHouse's platform model, with overlap in pharma buyer relationships.
  • Cradle Bio: Cradle applies generative AI to protein and biologics design, combining ML with wet-lab iteration. Its AI + biology productisation ethos is comparable, though its modality focus is proteins rather than plant small molecules.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

HotHouse Therapeutics social profiles

Digital presence

HotHouse Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HotHouse Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

HotHouse Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HotHouse Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HotHouse Therapeutics

What does HotHouse Therapeutics do?

HotHouse Therapeutics operates a dual-platform drug discovery architecture combining AI with plant-based bioengineering. The BotanAI platform initiates and optimizes compound design, while BotanBio delivers scalable chemistry through novel transient and stable plant expression systems. The company reprograms plant biosynthetic pathways to produce therapeutic compounds—including vaccine adjuvants and new-to-nature molecules—that are inaccessible through traditional chemical synthesis, moving from digital concept to high-purity compounds in days rather than years.

Is HotHouse Therapeutics a public or private company?

HotHouse Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was HotHouse Therapeutics founded?

HotHouse Therapeutics was founded in 2025. It employs 11 to 50 people.

Where is HotHouse Therapeutics based?

HotHouse Therapeutics is headquartered in Norwich, United Kingdom, in the Europe region.

How does HotHouse Therapeutics make money?

One revenue line is on record: drug Discovery Partnerships and Licensing.

Who are HotHouse Therapeutics's main competitors?

Broad incumbents on record are Isomorphic Labs, Recursion Pharmaceuticals, Schrödinger, Ginkgo Bioworks and Insilico Medicine. Direct peers are Antheia, Ayana Bio and Brightseed. Emerging players are Atomwise and Cradle Bio.

Does HotHouse Therapeutics have an API?

No public API is recorded for HotHouse Therapeutics.

What industry is HotHouse Therapeutics in?

HotHouse Therapeutics's product category is AI-Driven Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Five Finalists Announced For Cambridge Tech Week 2026 Pitching CompetitionFive UK startups have been selected as finalists for the Cambridge Tech Week 2026 Pitching Competition, chosen from a shortlist of 20 companies across artificial intelligence, biotechnology, sustainable energy, medtech, and agritech sectors. The finalists are HotHouse Therapeutics, HutanBio, Lambda Energy, Myonerv, and Xplore Intelligence, with Xplore Intelligence having already secured its first contract worth more than £1 million. The live competition will take place on September 16 at the Corn Exchange during Startup to Scaleup Day, with judges from Mills & Reeve, Metaxi Catalyst Ventures, Foresight Group, and Cambridge Angels.Chemical & Engineering NewsHotHouse launches to remix plant compound biosynthesis for pharmaHotHouse Therapeutics has emerged from stealth with over $3 million in preseed funding to apply AI and synthetic biology for reprogramming plant biosynthetic pathways. The company is currently producing the vaccine adjuvant QS-21 and its analogs as a proof-of-concept, aiming to develop sustainable pharmaceutical compounds.FinSMEsHotHouse Therapeutics Raises £2.9M in FundingHotHouse Therapeutics, a UK-based drug discovery platform developer, raised £2.9M in pre-seed funding from investors including SynBioVen and Start Codon. The company will use the funds to expand operations and R&D, focusing on vaccine adjuvants and planning traditional drug discovery programmes.EIN PresswireHotHouse Therapeutics implements CDD Vault to accelerate plant-inspired drug discoveryHotHouse Therapeutics, a UK biotech spin-out from the John Innes Centre specializing in plant-based drug discovery, has implemented CDD Vault, the cloud-based informatics platform from Collaborative Drug Discovery, to enhance its R&D operations. The platform enables the company to centralize experimental and computational data, accelerate lead design decisions, improve collaboration with partners, and maintain full control of intellectual property. Both companies expressed optimism about the partnership, with HotHouse citing the platform's adaptability for managing complex datasets in its AI-driven plant biosynthesis work.